Het onderzoek wordt bij gezonde personen uitgevoerd. Het onderzoek kan voor nieuwe inzichten zorgen bij therapeutische interventies voor pijn. not applicable
Conditions
Interventions
In the oxytocin group, participants will receive a 40 IU dose of oxytocin via a
nasal spray. In the placebo group, participants will receive a placebo spray.
The placebo and nocebo effects will be i
Sponsors
Universiteit Leiden
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Men between 18 and 35 years old - Good understanding of written and spoken English
Exclusion criteria
Exclusion criteria: - Refusal to give written informed consent - Conditions that might interfere with the participant's safety and/or the study protocol: severe somatic or psychological morbidity (e.g., heart and lung diseases, or DSM-IV psychiatric disorders) - Family history of an acute heart failure or death caused by an acute heart failure - Chronic or acute pain complaints - Current use of analgesics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is a difference between the oxytocin and placebo groups in the placebo effect. The placebo effect will be calculated as the difference in the subjective pain ratings between the yellow (control) and green (placebo) cues in the heat pain conditioning task in the testing phase. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary study parameter is the difference between the groups in the nocebo effect. The nocebo effect will be calculated as a difference in the subjective pain ratings between the red (nocebo) and yellow (control) cues in the heat pain conditioning task in the testing phase. | — |
Countries
Netherlands
Outcome results
None listed